Plain-English translation of NCT06450548 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether two types of advanced imaging scans — called dynamic PET scans — can better identify where prostate cancer has spread in your body compared to standard imaging. These scans use special tracers to light up cancer cells, and the study is designed to help doctors decide if 177Lu-PSMA-617, a new type of radiation treatment, is right for you before you start the medication.
Some prostate cancers show up differently on various scans, and these differences can tell doctors whether the treatment will work well or if the cancer may be harder to treat. This study aims to improve how doctors read these scans so they can make better treatment decisions upfront.
You likely qualify if…
You likely don't qualify if…
You will undergo two imaging scans — one with 18F-FDG tracer and one with 68Ga-PSMA tracer — that take detailed pictures of where cancer is growing in your body. Both scans involve receiving an injection of a safe radioactive tracer, waiting a period of time, and then lying still in a scanner for about an hour while images are taken. The two scans will be performed at least 24 hours apart but no more than 15 days apart, and the results will help your doctor determine if you are a good candidate for the new radiation treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France